Dallas, Texas 08/25/2014 (FINANCIALSTRENDS) – Aradigm Corporation (NASDAQ:ARDM) predict analysts in the bio technology sector is a diamond-mine like bio company waiting to be discovered by investors and industry experts alike.
The high recommendation for a largely respiratory-disease therapy developer comes from its latest quarterly results filed. The strong play of financial strength, followed by a well-backed presence due to various ties with leading pharmaceutical companies has been the fork-lift marking this companies’ prowess.
At the start of their argument, most analysts see that this stock is largely undervalued. Therefore, the risks associated with it are correspondingly less, remaining attractive to investors, say analysts. They suggest the upside seen due to the downside risk is ready for the pricking, for investors.
Aradigm Corporation (NASDAQ:ARDM) primary attractiveness is the drug pipeline it holds. Considering that its current drugs are targeted at a medical segment which is largely new, the advantages definitely favor Aradigm. The market size any of its drugs could reach are in the region of $25 billion.
This is already marked by the quick initial-approval of Pulmaquin so that the company may commence Phase 3 trails.
The primary driver in many ways for Aradigm Corporation (NASDAQ:ARDM) is the assorted tie-ups it has been able to establish with established biotechnology companies. A telling example of the success of its partnership is the 2013-dated agreement with Grifols S.A. as part of its licensing program for global sales.
In recent times the increase in pollution levels has definitely offset the respiratory disease causes, which fortunately for Aradigm offers immense scope for growth.
As medical expert at GBI Research Dr.Chang and Dr. Penny Wood elaborate, “There is more than one major unmet need for patients with lung conditions.” The experts also explained that, “these range from the need for improved diagnosis to appropriate treatment, care and increased research funding.”